I期临床-话题@MedSci

#I期临床#

570篇内容 | 7056人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652947, encodeId=9037165294e51, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=49, createdTime=2020-06-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652968, encodeId=a4be1652968cc, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=52, createdTime=2020-07-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652909, encodeId=5b6c165290968, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=斑蝥素治疗常见疣的II期临床研究取得积极成绩, objectType=article, longId=174339, objectId=2db21e433919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2db21e433919, replyNumber=0, likeNumber=66, createdTime=2019-08-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2db21e433919, moduleTitle=斑蝥素治疗常见疣的II期临床研究取得积极成绩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2db21e433919)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652875, encodeId=754a16528e5b8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=54, createdTime=2019-10-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652924, encodeId=3eae165292456, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果, objectType=article, longId=177617, objectId=12b31e761746, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12b31e761746, replyNumber=0, likeNumber=65, createdTime=2020-04-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12b31e761746, moduleTitle=Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12b31e761746)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652952, encodeId=334c16529528c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, objectType=article, longId=181894, objectId=a3881818949e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3881818949e, replyNumber=0, likeNumber=101, createdTime=2020-07-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3881818949e, moduleTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3881818949e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652879, encodeId=6fe616528e940, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=治疗卵巢癌和子宫内膜癌的抗体 - 药物偶联物（ADC）STRO-002将开启I期临床试验, objectType=article, longId=162524, objectId=507e16252443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=507e16252443, replyNumber=0, likeNumber=56, createdTime=2019-04-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=507e16252443, moduleTitle=治疗卵巢癌和子宫内膜癌的抗体 - 药物偶联物（ADC）STRO-002将开启I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=507e16252443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652911, encodeId=ec76165291118, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=85, createdTime=2019-12-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652902, encodeId=3e93165290231, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破, objectType=article, longId=167693, objectId=bf9916e693b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9916e693b0, replyNumber=0, likeNumber=80, createdTime=2020-02-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9916e693b0, moduleTitle=Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf9916e693b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652932, encodeId=fe2d165293256, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, objectType=article, longId=178689, objectId=11b21e8689cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11b21e8689cf, replyNumber=0, likeNumber=65, createdTime=2019-09-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11b21e8689cf, moduleTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11b21e8689cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652894, encodeId=77ae165289461, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, objectType=article, longId=165942, objectId=8c7e165942ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7e165942ca, replyNumber=0, likeNumber=82, createdTime=2020-03-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7e165942ca, moduleTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c7e165942ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652898, encodeId=be5d1652898ef, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, objectType=article, longId=166801, objectId=1b1b16680115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1b16680115, replyNumber=0, likeNumber=89, createdTime=2020-04-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1b16680115, moduleTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1b16680115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652890, encodeId=ce511652890f0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, objectType=article, longId=165882, objectId=9c0116588208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0116588208, replyNumber=0, likeNumber=61, createdTime=2019-05-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0116588208, moduleTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0116588208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652937, encodeId=4d30165293ee4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, objectType=article, longId=179755, objectId=246d1e9755d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246d1e9755d6, replyNumber=0, likeNumber=23, createdTime=2019-10-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246d1e9755d6, moduleTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246d1e9755d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652951, encodeId=6897165295162, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验, objectType=article, longId=181882, objectId=a91918188212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91918188212, replyNumber=0, likeNumber=0, createdTime=2019-12-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91918188212, moduleTitle=礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91918188212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652915, encodeId=2ccc16529154c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, objectType=article, longId=175120, objectId=15c11e51207f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c11e51207f, replyNumber=0, likeNumber=82, createdTime=2020-04-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c11e51207f, moduleTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c11e51207f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652934, encodeId=d8fd1652934c9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=50, createdTime=2020-05-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652919, encodeId=384016529196a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, objectType=article, longId=176224, objectId=18291e622416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18291e622416, replyNumber=0, likeNumber=68, createdTime=2020-04-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18291e622416, moduleTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18291e622416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652922, encodeId=64bd16529229d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=维罗纳制药使用干粉吸入的恩替芬碱治疗慢性阻塞性肺病II期临床结果喜人, objectType=article, longId=177340, objectId=018c1e7340aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=018c1e7340aa, replyNumber=0, likeNumber=65, createdTime=2020-04-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=018c1e7340aa, moduleTitle=维罗纳制药使用干粉吸入的恩替芬碱治疗慢性阻塞性肺病II期临床结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=018c1e7340aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652863, encodeId=658c1652863ef, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, objectType=article, longId=160421, objectId=524e160421b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524e160421b4, replyNumber=0, likeNumber=69, createdTime=2019-06-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524e160421b4, moduleTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=524e160421b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2020-06-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2020-07-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

斑蝥素治疗常见疣的II期临床研究取得积极成绩

2019-08-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功

2019-10-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果

2020-04-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益

2020-07-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

治疗卵巢癌和子宫内膜癌的抗体 - 药物偶联物（ADC）STRO-002将开启I期临床试验

2019-04-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-12-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破

2020-02-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功

2019-09-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药

2020-03-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果

2020-04-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

2019-05-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019

2019-10-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验

2019-12-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功

2020-04-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2020-05-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果

2020-04-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

维罗纳制药使用干粉吸入的恩替芬碱治疗慢性阻塞性肺病II期临床结果喜人

2020-04-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验

2019-06-08

科室
- - 订阅+
  - 更多科室
工具
服务